Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

stimulant

Associated Studies:

Division Study Number Title Investigator(s) Release Date
CTN NIDA-CTN-0068 Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder (ADAPT-2) Madhukar H. Trivedi, M.D.
CTN NIDA-CTN-0054 Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder (ADAPT) Walter Ling, M.D.
DTMC NIDA-CPU-0010 Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CTO-0011 Double-Blind, Placebo-Controlled, Dose Response Trial Of Ondansetron For The Treatment Of Methamphetamine Dependence Bankole Johnson, DSc., M.D., Ph.D.
DTMC NIDA-CTO-0012 Phase 2, Double-Blind, Placebo-Controlled Trial Of Tiagabine For The Treatment Of Cocaine Dependence Eugene Somoza, M.D.
DTMC NIDA-MDS-0002 Assessment of Interactions Between Methamphetamine and Aripiprazole Thomas F. Newton, M.D.
DTMC NIDA-CTO-0010 Assessment of Potential Interactions Between Methamphetamine and Bupropion Thomas F. Newton, M.D.
DTMC NIDA-CTO-0008 Phase 2, Double-Blind Placebo-Controlled Trial Of Bupropion for the Treatment of Methamphetamine Dependence Richard Rawson, Ph.D.
DTMC NIDA-CSP-1022 Phase 2, Double-Blind, Placebo-Controlled Trial Of Selegiline Transdermal System (STS) As An Aid For Smoking Cessation Elbert D. Glover, PhD, FASHA, FAAHB, FRIPH
DTMC NIDA-CSP-1021 Double-Blind, Placebo-Controlled Multi-Center Trial Of Baclofen For The Treatment Of Cocaine Dependence Liza Gorgon, M.A.
DTMC NIDA-CSP-1019 Double-Blind, Placebo-Controlled Trial Of Selegiline Transdermal System For The Treatment Of Cocaine Dependence Ahmed Elkashef, M.D., Paul J. Fudala, Ph.D.
DTMC NIDA-MDS-0003 Phase I, Double-Blind, Placebo-Controlled Assessment Of Potential Interactions Between Intravenous Cocaine And Ethanol And Oral Disulfiram John D. Roache, Ph.D.
DTMC NIDA-CPU-0008 Double-Blind, Placebo-Controlled Assessment of Interactions Between Intravenous Methamphetamine and Modafinil Reese Jones, M.D.
DTMC NIDA-CTO-0007 Phase 2, Double-Blind, Placebo-Controlled Trial Of Cabergoline For The Treatment Of Cocaine Dependence Steven Shoptaw, Ph.D., Thomas F. Newton, M.D.
DTMC NIDA-CPU-0005 Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CPU-0004 Study of Interactions Between GBR 12909 and Cocaine Kathryn Cunningham, Ph.D., John Grabowski, Ph.D.
DTMC NIDA-CPU-0006 A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine Reese Jones, M.D.
DTMC NIDA-CPU-0003 Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681 Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CPU-0002 Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CTO-0006 Cocaine-Metyrapone Interaction Study Bonita Singal, M.D., T. John Winhusen, Ph.D.
DTMC NIDA-CTO-0005 Double-Blind, Placebo-Controlled Trial Of Ondansetron For The Treatment Of Cocaine Dependence John D. Roache, Ph.D.
DTMC NIDA-CTO-0004 Assessment Of Potential Interactions Between Intravenous Methamphetamine And Oral Selegiline Thomas F. Newton, M.D.
DTMC NIDA-CTO-0003 Assessment Of Potential Interactions Between Intravenous Cocaine And Tolcapone Thomas F. Newton, M.D.
DTMC NIDA-MDS-0007 Phase 2, Double-Blind, Placebo-Controlled Trial Of Bupropion For Methamphetamine Dependence Ann Anderson, M.D.
DTMC NIDA-MDS-0004 Phase 2, Double-Blind, Placebo-Controlled Trial Of Modafinil For The Treatment Of Cocaine Dependence Domenic Ciraulo, M.D.
DTMC NIDA-CTO-0001 Phase 2, Double-Blind, Placebo-Controlled Trial Of Reserpine For The Treatment Of Cocaine Dependence Eugene Somoza, M.D.
CTN NIDA-CTN-0052 A Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults with Cocaine Dependence (BRAC) T. John Winhusen, Ph.D.
CTN NIDA-CTN-0046 Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes T. John Winhusen, Ph.D., Eugene Somoza, M.D.
CTN NIDA-CTN-0037 Stimulant Reduction Intervention using Dosed Exercise (STRIDE) Madhukar H. Trivedi, M.D.
CTN NIDA-CTN-0031A An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association With Treatment Outcomes in Methamphetamine and Cocaine Abusers T. John Winhusen, Ph.D., Eugene Somoza, M.D.
CTN NIDA-CTN-0031 Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement Dennis Donovan, Ph.D., Dennis Daley, Ph.D.
DTMC NIDA-CSP-1026 Phase 2, Double-Blind, Placebo-Controlled Trial Of Modafinil For Methamphetamine Dependence Ahmed Elkashef, M.D.
DTMC NIDA-CSP-1025 Phase 2, Double-Blind, Placebo-Controlled Trial Of Topiramate For The Treatment Of Methamphetamine Dependence Bankole Johnson, DSc., M.D., Ph.D.
DTMC NIDA-CPU-0016 Double-Blind, Placebo-Controlled Assessment Of Potential Interactions Between Intravenous Methamphetamine And Osmotic-Release Methylphenidate (Oros-Mph) Eugene Somoza, M.D.
Subscribe to stimulant